6yd9

Publication Abstract from PubMed

We designed and synthesized a series of inhibitors of the bacterial enzymes DNA gyrase and DNA topoisomerase IV, based on our recently published benzothiazole-based inhibitor bearing an oxalyl moiety. To improve the antibacterial activity and retain potent enzymatic activity, we systematically explored the chemical space. Several strategies of modification were followed: varying substituents on the pyrrole carboxamide moiety, alteration of the central scaffold, including variation of substitution position and, most importantly, modification of the oxalyl moiety. Compounds with acidic, basic, and neutral properties were synthesized. To understand the mechanism of action and binding mode, we have obtained a crystal structure of compound 16a, bearing a primary amino group, in complex with the N-terminal domain of E. coli gyrase B (24 kDa) (PDB: 6YD9). Compound 15a, with a low molecular weight of 383 Da, potent inhibitory activity on E. coli gyrase (IC50 = 9.5 nM), potent antibacterial activity on E. faecalis (MIC = 3.13 muM), and efflux impaired E. coli strain (MIC = 0.78 muM), is an important contribution for the development of novel gyrase and topoisomerase IV inhibitors in Gram-negative bacteria.

Exploring the Chemical Space of Benzothiazole-Based DNA Gyrase B Inhibitors.,Skok Z, Barancokova M, Benek O, Cruz CD, Tammela P, Tomasic T, Zidar N, Masic LP, Zega A, Stevenson CEM, Mundy JEA, Lawson DM, Maxwell A, Kikelj D, Ilas J ACS Med Chem Lett. 2020 Oct 15;11(12):2433-2440. doi:, 10.1021/acsmedchemlett.0c00416. eCollection 2020 Dec 10. PMID:33329764^[4]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.